Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308542973> ?p ?o ?g. }
- W4308542973 abstract "All EU countries have introduced Human papilloma virus (HPV) vaccination for adolescent girls and many countries are expanding the strategy to include adolescent boys. There is uncertainty about the cost-effectiveness and epidemiological impact of a gender-neutral HPV vaccination strategy. Here we present the results of an economic model adapted for Spain. Five vaccination strategies were compared from the Spanish healthcare system perspective, combining two vaccines (4-valent and 9-valent) in a gender-neutral or girls-only programme in a dynamic population-based model with a discrete-time Markov approach. Costs and benefits were discounted at 3%. The benefits of immunization were measured with quality-adjusted life years (QALYs), which are achieved by reducing the incidence of diseases attributable to HPV. Incremental cost-effectiveness ratio (ICER) was compared with the willingness-to-pay threshold in Spain. The two most effective strategies were compared: gender-neutral 9-valent vaccination vs. girls-only 9-valent vaccination, resulting in an ICER of € 34,040/QALY, and an important number of prevented cases of invasive cancers and anogenital warts. The sensitivity analysis revealed that gender-neutral 9-valent vaccination would become cost-effective if protection against oropharyngeal and penile cancers was included or if the price per dose decreased from €45 to €28. The gender-neutral 9-valent HPV vaccination in Spain offers more benefits than any other modeled strategy, although in the conservative base case it is not cost-effective. However, certain plausible assumptions would turn it into an efficient strategy, which should be borne in mind by the decision makers together with equity and justice arguments.What is the context? Human papillomavirus (HPV) is a group of viruses that causes sexually transmitted diseases, including certain cancers. European countries offer HPV vaccination to adolescent girls.Many countries have also introduced the vaccination in adolescent boys.There are doubts about whether it is worth vaccinating adolescents of both genders.What this study adds? We estimated costs and benefits of the vaccination in Spain, comparing two types of vaccine, only in girls and in both genders. This analysis considered indirect protection of vaccinated people to unvaccinated ones.It seems that the benefits of HPV vaccination in all adolescents do not compensate the costs.However, when we included likely protection against additional cancers or we reduced the price per vaccine dose, it would be worth vaccinating all adolescents in Spain.We also stated ethical arguments in favor of HPV vaccination for both genders.What is the impact? HPV vaccination in adolescent boys and girls in Spain will prevent more HPV-related diseases.For certain scenarios, HPV vaccination in both genders would be worth in Spain.Ethically, vaccinating also boys would be fair, equitable and would not discriminate a part of the population." @default.
- W4308542973 created "2022-11-12" @default.
- W4308542973 creator A5004062547 @default.
- W4308542973 creator A5028462381 @default.
- W4308542973 creator A5044856828 @default.
- W4308542973 creator A5062987104 @default.
- W4308542973 date "2022-11-08" @default.
- W4308542973 modified "2023-09-25" @default.
- W4308542973 title "Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain" @default.
- W4308542973 cites W1979600349 @default.
- W4308542973 cites W1981725818 @default.
- W4308542973 cites W1992519297 @default.
- W4308542973 cites W2055349645 @default.
- W4308542973 cites W2060763328 @default.
- W4308542973 cites W2070338467 @default.
- W4308542973 cites W2130505310 @default.
- W4308542973 cites W2140741940 @default.
- W4308542973 cites W2143475618 @default.
- W4308542973 cites W2416462386 @default.
- W4308542973 cites W2470415918 @default.
- W4308542973 cites W2501112626 @default.
- W4308542973 cites W2587519223 @default.
- W4308542973 cites W2595252081 @default.
- W4308542973 cites W2605470218 @default.
- W4308542973 cites W2734446500 @default.
- W4308542973 cites W2738089573 @default.
- W4308542973 cites W2753649550 @default.
- W4308542973 cites W2775514712 @default.
- W4308542973 cites W2791010220 @default.
- W4308542973 cites W2791721480 @default.
- W4308542973 cites W2799516170 @default.
- W4308542973 cites W2802769862 @default.
- W4308542973 cites W2884212051 @default.
- W4308542973 cites W2910008965 @default.
- W4308542973 cites W2912326121 @default.
- W4308542973 cites W2952289677 @default.
- W4308542973 cites W2971395672 @default.
- W4308542973 cites W3012598757 @default.
- W4308542973 cites W3013109195 @default.
- W4308542973 cites W3036651224 @default.
- W4308542973 cites W3175966180 @default.
- W4308542973 cites W3204615344 @default.
- W4308542973 doi "https://doi.org/10.1080/21645515.2022.2127983" @default.
- W4308542973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36347243" @default.
- W4308542973 hasPublicationYear "2022" @default.
- W4308542973 type Work @default.
- W4308542973 citedByCount "2" @default.
- W4308542973 countsByYear W43085429732023 @default.
- W4308542973 crossrefType "journal-article" @default.
- W4308542973 hasAuthorship W4308542973A5004062547 @default.
- W4308542973 hasAuthorship W4308542973A5028462381 @default.
- W4308542973 hasAuthorship W4308542973A5044856828 @default.
- W4308542973 hasAuthorship W4308542973A5062987104 @default.
- W4308542973 hasBestOaLocation W43085429731 @default.
- W4308542973 hasConcept C107130276 @default.
- W4308542973 hasConcept C112930515 @default.
- W4308542973 hasConcept C126322002 @default.
- W4308542973 hasConcept C127454912 @default.
- W4308542973 hasConcept C144024400 @default.
- W4308542973 hasConcept C149923435 @default.
- W4308542973 hasConcept C162324750 @default.
- W4308542973 hasConcept C175444787 @default.
- W4308542973 hasConcept C17744445 @default.
- W4308542973 hasConcept C199539241 @default.
- W4308542973 hasConcept C203014093 @default.
- W4308542973 hasConcept C22070199 @default.
- W4308542973 hasConcept C2777364431 @default.
- W4308542973 hasConcept C2908647359 @default.
- W4308542973 hasConcept C3019080777 @default.
- W4308542973 hasConcept C515549039 @default.
- W4308542973 hasConcept C71924100 @default.
- W4308542973 hasConcept C99454951 @default.
- W4308542973 hasConceptScore W4308542973C107130276 @default.
- W4308542973 hasConceptScore W4308542973C112930515 @default.
- W4308542973 hasConceptScore W4308542973C126322002 @default.
- W4308542973 hasConceptScore W4308542973C127454912 @default.
- W4308542973 hasConceptScore W4308542973C144024400 @default.
- W4308542973 hasConceptScore W4308542973C149923435 @default.
- W4308542973 hasConceptScore W4308542973C162324750 @default.
- W4308542973 hasConceptScore W4308542973C175444787 @default.
- W4308542973 hasConceptScore W4308542973C17744445 @default.
- W4308542973 hasConceptScore W4308542973C199539241 @default.
- W4308542973 hasConceptScore W4308542973C203014093 @default.
- W4308542973 hasConceptScore W4308542973C22070199 @default.
- W4308542973 hasConceptScore W4308542973C2777364431 @default.
- W4308542973 hasConceptScore W4308542973C2908647359 @default.
- W4308542973 hasConceptScore W4308542973C3019080777 @default.
- W4308542973 hasConceptScore W4308542973C515549039 @default.
- W4308542973 hasConceptScore W4308542973C71924100 @default.
- W4308542973 hasConceptScore W4308542973C99454951 @default.
- W4308542973 hasFunder F4320311419 @default.
- W4308542973 hasIssue "6" @default.
- W4308542973 hasLocation W43085429731 @default.
- W4308542973 hasLocation W43085429732 @default.
- W4308542973 hasLocation W43085429733 @default.
- W4308542973 hasOpenAccess W4308542973 @default.
- W4308542973 hasPrimaryLocation W43085429731 @default.
- W4308542973 hasRelatedWork W1997992770 @default.
- W4308542973 hasRelatedWork W2001870732 @default.
- W4308542973 hasRelatedWork W2005688880 @default.